FUSMobile

FUSMobile Overview

FUSMobile advances noninvasive solutions for chronic painful conditions in order to improve the patient experience and clinical outcomes while reducing costs for healthcare providers and payers. The companys Neurolyser is a focused ultrasound treatment platform designed to relieve the suffering caused by a range of common conditions, including chronic lower back (facet joint) pain, knee and hip arthritis, sacroiliitis, and bone metastases. The completely noninvasive solution thermally ablates nerves without the risks, pain, high costs, and extensive training required by more invasive methods. FUSMobiles Neurolyser XR focused ultrasound device has finished its first-in-human study with excellent results and will soon enter pivotal clinical trials in pursuit of North American regulatory approval for facet joint arthritis, the first of many pain-related indications with potential benefits over currently available interventional pain treatments.

Cumulative Funding Raised Over Time ($)

Latest News

May 12, 2019 · www.israel21c.org

growth-positive

9 emerging devices that will disrupt health care

The 18th annual MIXiii-Biomed Conference and Exhibition in Tel Aviv will showcase cutting-edge medical devices that have the potential to disrupt the healthcare field. The event will bring together over 1,000 scientists, key opinion leaders, entrepreneurs, and investors from 45 countries, along with 5,000 Israeli counterparts. The sessions will cover topics such as gene editing, gene therapy, artificial intelligence, digital health, personalized medicine, transformative cancer therapies, new cell therapies, and medical cannabis. The conference aims to highlight disruptive technologies that can bring significant value and benefit to patients by changing current medical practices. While developing disruptive medical technology can be challenging and risky, it offers high potential for investment returns.

Customers

Oct 18, 2017 · www.fusfoundation.org

growth-positive

Clinical Trial Begins in Canada for Facet Arthritis Low Back Pain

FUSMobile, a focused ultrasound company, has opened enrollment for its first clinical study in Canada. The study aims to assess the safety and efficacy of the Neurolyser device in treating facet-related low back pain. The trial will be conducted at McGill Universitys Alan Edwards Pain Management Centre and will enroll ten Canadian residents. FUSMobile aims to provide non-invasive, office-based focused ultrasound devices that are highly efficient and cost-effective.

Customers

Aug 29, 2016 · blogs.biomedcentral.com

growth-positive

High Intensity Focused Ultrasound: A novel and non-invasive approach to target tumors - On Medicine

The article discusses the use of High Intensity Focused Ultrasound (HIFU) as a non-invasive therapeutic alternative for tumors and pain. The author shares their experience with HIFU and highlights its benefits for patients. The article also mentions the recent FDA approvals of HIFU devices for various medical conditions. The author discusses the current state of HIFU technology, which is mostly composed of expensive high-end platforms. The author introduces FUSMobile, a company aiming to provide low-cost HIFU devices for small-scale medical practices. The company has developed a platform called The Neurolyser, which is focused on pain management procedures. The article emphasizes the advantages of targeting small-scale practices and low-cost devices in terms of adoption and sales cycle. The Neurolyser platform has completed extensive R&D and is ready for market.

Customers

Funding

Team Members

2

Employees: 11-50

Web & Social Links

Locations

Sderot HaNadiv 5, Haifa, Israel

2972 Webb Bridge Rd, Alpharetta, GA, USA

Photos & Videos

1 item(s)

FUSMobile Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info